REG - Nuformix PLC - Result of Annual General Meeting

NuformixAnnouncement

24/08/2023 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230824:nRSX3775Ka&default-theme=true

RNS Number : 3775K  Nuformix PLC  24 August 2023

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing,  announces that
the Annual General Meeting of Nuformix plc was held earlier today and all
resolutions put to shareholders were duly passed and approved on a show of
hands at the meeting.

The results of the proxies appointing the Chair of the meeting are reported
below:

 

     Resolution                                                           Ordinary/ Special  For                  Against              Total votes cast
                                                                                             No. of votes  %      No. of votes  %
 1   To re-appoint Daniel Gooding as a director                           Ordinary           94,720,614    99.67  312,357       0.33%  95,032,971

 2   To re-appoint Julian Gilbert as a director                           Ordinary           94,720,614    99.67  312,357       0.33%  95,032,971

 3   To re-appoint s Madeleine Kennedy as a director                      Ordinary           92,448,034    99.66  312,357       0.34%  92,760,391

 4   To authorise the Directors to allot shares.                          Ordinary           92,082,014    96.19  3,652,015     3.81%  95,734,029

 5   To authorise the Directors to disapply pre-emption rights.           Special            92,082,014    98.52  1,379,435     1.48%  93,461,449

 6   To authorise the Company to purchase its own shares.                 Special            92,306,372    96.32  3,527,841     3.68%  95,834,213

 7   To authorise calling of a general meeting on 14 clear days' notice.  Special            93,093,402    97.14  2,740,811     2.86%  95,834,213

 

A vote withheld is not a vote in law and is not counted in the calculation of
votes validly cast for or against a resolution.

The Company's issued share capital is 744,309,368 ordinary shares of £0.001
each.

Enquiries:

 

 Nuformix plc
 Dr Daniel Gooding, Executive Director             Via IFC Advisory

 Dr Julian Gilbert, Non-executive Chairman

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical and Phase
1-ready assets with potential for significant value and early licensing
opportunities.

 

For more information, please visit www.nuformix.com
(http://www.nuformix.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFLFFFTLISFIV